Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket studyLingfang Xia, Xiaohua Wu, Ge Lou et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 39